Research programme: protein kinase inhibitors - Locus/SciosAlternative Names: Protein kinase inhibitors research programme - Locus/Scios
Latest Information Update: 21 Jan 2010
At a glance
- Originator Locus Pharmaceuticals; Scios
- Class Small molecules
- Mechanism of Action Protein kinase inhibitors
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
On Fast track
Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.
Highest Development Phases
- Discontinued Unspecified
Most Recent Events
- 14 Mar 2005 Early research in an undefined indication in the US (unspecified route)